The Blushield Pilot Study: What the Peer-Reviewed Research Found

A plain-English guide to the first published human study of Blushield.

In 2024, a pilot study of Blushield was published in the peer-reviewed journal Integrative Medicine and indexed on PubMed. It's the first published human study of Blushield, and one of very few published studies of any powered EMF device used in real homes.

This page covers what the study set out to do, what it found, and what it can't yet tell us.

About the study

Title: A Pilot Study Evaluating the Feasibility and Efficacy of an In-Home Resonance-Based Electromagnetic Field Protection Device

Authors: D'Adamo CR, Denmark D, Carreras-Gallo N, Dwaraka V, Smith R, Blue T, Messier H

Published: Integrative Medicine (Encinitas), 2024

PubMed ID: 39355415

Trial registration: ClinicalTrials.gov NCT05001646

Ethics: Approved by an independent review board (IRB).

Funding: The study was funded by Blushield USA, Blushield's US distributor. [VERIFY against the paper's funding and conflict of interest statement]

How the study worked

25 healthy adults used Blushield devices in their own homes for 12 weeks. They carried on using their phones, Wi-Fi and everyday technology as normal.

The researchers tracked a wide range of health markers at the start and end of the study:

Heart rate variability (HRV), a marker of nervous system balance and recovery, measured with Oura Ring wearables.
Sleep, including deep sleep, also measured with Oura Rings.
Cognitive function, including memory, mental flexibility and processing speed, measured with standardised neurocognitive tests.
Blood markers, including blood glucose, from laboratory panels.
DNA methylation, a measure of how genes are switched on or off.
Self-reported health, from questionnaires.

Every participant completed the study (100% compliance).

What the study found

Over 12 weeks, the researchers reported statistically significant changes across several markers:

Marker	What changed	Significance
Heart rate variability	Improved	p < 0.04
Deep sleep	Improved	p < 0.04
Cognitive function	Improved (memory, flexibility, processing)	p < 0.02
Blood glucose	Decreased, from healthy baselines	p < 0.04
CACNA1G gene	Methylation normalised	p = 0.000045
Self-reported health	Improved	p = 0.02

No device-related adverse events were reported.

The authors concluded that the device was feasible and safe, and associated with improvements across these markers. They described it as "a reasonable component of a more comprehensive EMF mitigation strategy".

Why the CACNA1G finding matters

CACNA1G is a gene that codes for part of a voltage-gated calcium channel. These channels control how calcium moves in and out of cells. Some researchers, most notably Professor Martin Pall, have proposed that these channels are one of the main ways the body responds to EMF.

The study found changes in how this gene was methylated over 12 weeks. On its own, this doesn't prove how Blushield works. It does give researchers a specific, measurable lead to follow in future studies.

What a "p-value" means

A p-value shows how likely it is that a result happened by chance. A p-value below 0.05 is the usual threshold for calling a result "statistically significant". The lower the number, the less likely the result is due to chance.